Skip to main content

Protalix BioTherapeutics, Inc.

corporate_fare Company Profile

Protalix BioTherapeutics, Inc.

PLX·NYSE·Life Sciences·CIK 0001006281

Protalix BioTherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. It is the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. Its proprietary plant cell-based protein expression system, ProCellEx®, represents a new method for developing recombinant proteins on an industrial scale. The company's corporate strategy includes development of treatments for rare and orphan diseases, with a focus on new, early-stage product candidates for indications with high unmet needs in efficacy and safety, including renal diseases. It intends to use the ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies. Consistent with this strategy, it is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, and Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, along with a number of other technologies and preclinical assets. It has completed a Phase 1 First-in-Human clinical trial of PRX-115 and is actively recruiting for a Phase 2 clinical trial of PRX-115 for uncontrolled gout, referred to as the RELEASE study, in which the first patients have been randomized. To date, Protalix BioTherapeutics has successfully developed two commercial products, both enzyme replacement therapies (ERTs): Elelyso® (taliglucerase alfa) for the treatment of adult patients and children four years of age and older with Gaucher disease, and Elfabrio® (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease. Elelyso, its first commercial product, is its proprietary recombinant form of glucocerebrosidase (GCD), an enzyme naturally found in human cells that is mutated or deficient in patients with Gaucher disease.

Protalix BioTherapeutics, Inc. (NYSE:PLX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for PLX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 7/10. Recent SEC coverage for PLX spans 10-Q, 8-K.

Recent high-impact activity:

  • Protalix 10-Q: $26.1M Nine-Month Profit, $48.5M Cash, No Debt
  • Protalix Q3 2026: Net Income $4.0M, YTD Revenue $75.6M, 2026 Guidance Reaffirmed

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$52.74M
Net Income
-$6.6M
Diluted EPS
-$0.08
Op. Cash Flow
-$11.99M
Free Cash Flow
-$13.63M
Gross Profit
$25.75M
Operating Income
-$5.5M
Cash & Equivalents
$14.68M
Debt / Equity
0.00×
Net Margin
-12.5%
Shares Outstanding
80.43M sh
Source: 10-K · filed 2026-03-18 · accession 0001104659-26-029858

Short Interest & Short Volume

6.18 days to cover

FINRA reported short interest of 3,480,033 shares in PLX as of the October 30, 2026 settlement, a 0.8% decrease from the prior period — about 6.2 days to cover at its recent average daily volume. On November 19, 2026, 34.9% of PLX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,480,033 shares as of October 30, 2026
Change vs prior period▼ 0.8%
Days to cover6.18 at avg daily volume of 563,101
Daily short volume (FINRA facilities)34.9% of 812,239 shares on November 19, 2026
5-day average short volume31.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$2.89 -5.56% today
52-week range · as of 2026-11-10 $1.65 – $3.19
Market cap
$242.42M
Volume
1.1M (1.1× avg)
3-mo avg 1M
Live data · 2026-11-20 20:47 UTC · Market open

show_chartPrice Chart

Loading chart...

feed PLX - Latest Insights

PLX
Nov 10, 2026, 7:04 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.58
Real-time Price: $2.89 info
Change: +$0.3095 (+12%) info
Market Cap: $242.417M info
PLX
Nov 10, 2026, 6:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.71
Real-time Price: $2.89 info
Change: +$0.180 (+7%) info
Market Cap: $242.417M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets